ID   NTRK1_HUMAN             Reviewed;         796 AA.
AC   P04629; B2R6T5; B7ZM34; P08119; Q15655; Q15656; Q5D056; Q5VZS2;
AC   Q7Z5C3; Q9UIU7;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   02-MAY-2006, sequence version 4.
DT   10-MAY-2017, entry version 224.
DE   RecName: Full=High affinity nerve growth factor receptor;
DE            EC=2.7.10.1 {ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:2927393};
DE   AltName: Full=Neurotrophic tyrosine kinase receptor type 1;
DE   AltName: Full=TRK1-transforming tyrosine kinase protein;
DE   AltName: Full=Tropomyosin-related kinase A;
DE   AltName: Full=Tyrosine kinase receptor;
DE   AltName: Full=Tyrosine kinase receptor A;
DE            Short=Trk-A;
DE   AltName: Full=gp140trk {ECO:0000303|PubMed:2927393};
DE   AltName: Full=p140-TrkA;
DE   Flags: Precursor;
GN   Name=NTRK1;
GN   Synonyms=MTC, TRK {ECO:0000303|PubMed:2927393},
GN   TRKA {ECO:0000303|PubMed:9290260};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKA-I), CATALYTIC ACTIVITY,
RP   PHOSPHORYLATION, GLYCOSYLATION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Colon;
RX   PubMed=2927393; DOI=10.1128/MCB.9.1.24;
RA   Martin-Zanca D., Oskam R., Mitra G., Copeland T.D., Barbacid M.;
RT   "Molecular and biochemical characterization of the human trk proto-
RT   oncogene.";
RL   Mol. Cell. Biol. 9:24-33(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=7823156;
RA   Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P.,
RA   Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.;
RT   "Human trks: molecular cloning, tissue distribution, and expression of
RT   extracellular domain immunoadhesins.";
RL   J. Neurosci. 15:477-491(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9290260; DOI=10.1007/BF02766957;
RA   Indo Y., Mardy S., Tsuruta M., Karim M.A., Matsuda I.;
RT   "Structure and organization of the human TRKA gene encoding a high
RT   affinity receptor for nerve growth factor.";
RL   Jpn. J. Hum. Genet. 42:343-351(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKA-II), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-175 (ISOFORM 3).
RC   TISSUE=Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS TRKA-I AND TRKA-II).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-71.
RX   PubMed=15870692; DOI=10.1038/sj.onc.1208697;
RA   Fujimoto M., Kitazawa R., Maeda S., Kitazawa S.;
RT   "Methylation adjacent to negatively regulating AP-1 site reactivates
RT   TrkA gene expression during cancer progression.";
RL   Oncogene 24:5108-5118(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796, AND CHROMOSOMAL TRANSLOCATION
RP   WITH TPM3.
RX   PubMed=2869410; DOI=10.1038/319743a0;
RA   Martin-Zanca D., Hughes S.H., Barbacid M.;
RT   "A human oncogene formed by the fusion of truncated tropomyosin and
RT   protein tyrosine kinase sequences.";
RL   Nature 319:743-748(1986).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796.
RX   PubMed=2966065;
RA   Kozma S.C., Redmond S.M.S., Saurer S.M., Groner B., Hynes N.E.;
RT   "Activation of the receptor kinase domain of the trk oncogene by
RT   recombination with two different cellular sequences.";
RL   EMBO J. 7:147-154(1988).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796, AND CHROMOSOMAL TRANSLOCATION
RP   WITH TFG.
RX   PubMed=7565764; DOI=10.1128/MCB.15.11.6118;
RA   Greco A., Mariani C., Miranda C., Lupas A., Pagliardini S., Pomati M.,
RA   Pierotti M.A.;
RT   "The DNA rearrangement that generates the TRK-T3 oncogene involves a
RT   novel gene on chromosome 3 whose product has a potential coiled-coil
RT   domain.";
RL   Mol. Cell. Biol. 15:6118-6127(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 486-796, AND CHROMOSOMAL REARRANGEMENT
RP   WITH TPR.
RX   PubMed=1532241;
RA   Greco A., Pierotti M.A., Bongarzone I., Pagliardini S., Lanzi C.,
RA   Della Porta G.;
RT   "TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes
RT   in human papillary thyroid carcinomas.";
RL   Oncogene 7:237-242(1992).
RN   [12]
RP   FUNCTION AS RECEPTOR FOR NGF.
RX   PubMed=1850821; DOI=10.1038/350678a0;
RA   Hempstead B.L., Martin-Zanca D., Kaplan D.R., Parada L.F., Chao M.V.;
RT   "High-affinity NGF binding requires coexpression of the trk proto-
RT   oncogene and the low-affinity NGF receptor.";
RL   Nature 350:678-683(1991).
RN   [13]
RP   FUNCTION IN NGF SIGNALING, AND IDENTIFICATION AS THE HIGH AFFINITY NGF
RP   RECEPTOR.
RX   PubMed=1849459; DOI=10.1016/0092-8674(91)90419-Y;
RA   Klein R., Jing S., Nanduri V., O'Rourke E., Barbacid M.;
RT   "The trk proto-oncogene encodes a receptor for nerve growth factor.";
RL   Cell 65:189-197(1991).
RN   [14]
RP   FUNCTION, SUBUNIT, CATALYTIC ACTIVITY, PHOSPHORYLATION, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF LYS-544.
RX   PubMed=1281417; DOI=10.1016/0896-6273(92)90066-M;
RA   Jing S., Tapley P., Barbacid M.;
RT   "Nerve growth factor mediates signal transduction through trk
RT   homodimer receptors.";
RL   Neuron 9:1067-1079(1992).
RN   [15]
RP   ALTERNATIVE SPLICING (ISOFORMS TRKA-I AND TRKA-II), FUNCTION IN CELL
RP   SURVIVAL, NGF-BINDING, PHOSPHORYLATION, AND TISSUE SPECIFICITY.
RX   PubMed=8325889;
RA   Barker P.A., Lomen-Hoerth C., Gensch E.M., Meakin S.O., Glass D.J.,
RA   Shooter E.M.;
RT   "Tissue-specific alternative splicing generates two isoforms of the
RT   trkA receptor.";
RL   J. Biol. Chem. 268:15150-15157(1993).
RN   [16]
RP   PHOSPHORYLATION AT TYR-791, INTERACTION WITH PLCG1, AND MUTAGENESIS OF
RP   TYR-791.
RX   PubMed=7510697;
RA   Loeb D.M., Stephens R.M., Copeland T.D., Kaplan D.R., Greene L.A.;
RT   "A Trk nerve growth factor (NGF) receptor point mutation affecting
RT   interaction with phospholipase C-gamma 1 abolishes NGF-promoted
RT   peripherin induction but not neurite outgrowth.";
RL   J. Biol. Chem. 269:8901-8910(1994).
RN   [17]
RP   FUNCTION IN NEURONAL DIFFERENTIATION, FUNCTION IN PHOSPHORYLATION OF
RP   SHC1 AND PLCG1, INTERACTION WITH SHC1, MUTAGENESIS OF TYR-496; LYS-544
RP   AND TYR-791, AND PHOSPHORYLATION AT TYR-496 AND TYR-791.
RX   PubMed=8155326; DOI=10.1016/0896-6273(94)90223-2;
RA   Stephens R.M., Loeb D.M., Copeland T.D., Pawson T., Greene L.A.,
RA   Kaplan D.R.;
RT   "Trk receptors use redundant signal transduction pathways involving
RT   SHC and PLC-gamma 1 to mediate NGF responses.";
RL   Neuron 12:691-705(1994).
RN   [18]
RP   FUNCTION IN NF-KAPPA-B ACTIVATION, AND INTERACTION WITH SQSTM1.
RX   PubMed=11244088; DOI=10.1074/jbc.C000869200;
RA   Wooten M.W., Seibenhener M.L., Mamidipudi V., Diaz-Meco M.T.,
RA   Barker P.A., Moscat J.;
RT   "The atypical protein kinase C-interacting protein p62 is a scaffold
RT   for NF-kappaB activation by nerve growth factor.";
RL   J. Biol. Chem. 276:7709-7712(2001).
RN   [19]
RP   FUNCTION IN NEURONAL CELL PROLIFERATION AND DIFFERENTIATION, FUNCTION
RP   IN SIGNALING CASCADE ACTIVATION, NGF-BINDING, SUBCELLULAR LOCATION,
RP   ALTERNATIVE SPLICING (ISOFORM TRKA-III), CHARACTERIZATION OF ISOFORM
RP   TRKA-III, PHOSPHORYLATION AT TYR-496; TYR-680; TYR-681 AND TYR-791,
RP   INTERACTION WITH FRS2; GRB2; PIK3R1; PLCG1; SHC1, GLYCOSYLATION,
RP   TISSUE SPECIFICITY, AND INDUCTION BY HYPOXIA.
RX   PubMed=15488758; DOI=10.1016/j.ccr.2004.09.011;
RA   Tacconelli A., Farina A.R., Cappabianca L., Desantis G., Tessitore A.,
RA   Vetuschi A., Sferra R., Rucci N., Argenti B., Screpanti I., Gulino A.,
RA   Mackay A.R.;
RT   "TrkA alternative splicing: a regulated tumor-promoting switch in
RT   human neuroblastoma.";
RL   Cancer Cell 6:347-360(2004).
RN   [20]
RP   INTERACTION WITH SORT1, AND ENZYME REGULATION.
RX   PubMed=21102451; DOI=10.1038/nn.2689;
RA   Vaegter C.B., Jansen P., Fjorback A.W., Glerup S., Skeldal S.,
RA   Kjolby M., Richner M., Erdmann B., Nyengaard J.R., Tessarollo L.,
RA   Lewin G.R., Willnow T.E., Chao M.V., Nykjaer A.;
RT   "Sortilin associates with Trk receptors to enhance anterograde
RT   transport and neurotrophin signaling.";
RL   Nat. Neurosci. 14:54-61(2011).
RN   [21]
RP   STRUCTURE BY NMR OF 489-500.
RX   PubMed=8524391; DOI=10.1038/378584a0;
RA   Zhou M.-M., Ravichandran K.S., Olejniczak E.F., Petros A.M.,
RA   Meadows R.P., Sattler M., Harlan J.E., Wade W.S., Burakoff S.J.,
RA   Fesik S.W.;
RT   "Structure and ligand recognition of the phosphotyrosine binding
RT   domain of Shc.";
RL   Nature 378:584-592(1995).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 278-386, AND DISULFIDE
RP   BONDS.
RX   PubMed=10388563; DOI=10.1006/jmbi.1999.2816;
RA   Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M.,
RA   Reilly D., Bass S.H., de Vos A.M.;
RT   "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB
RT   and TrkC.";
RL   J. Mol. Biol. 290:149-159(1999).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 282-382 IN COMPLEX WITH NGF,
RP   SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=10490030; DOI=10.1038/43705;
RA   Wiesmann C., Ultsch M.H., Bass S.H., de Vos A.M.;
RT   "Crystal structure of nerve growth factor in complex with the ligand-
RT   binding domain of the TrkA receptor.";
RL   Nature 401:184-188(1999).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (3.4 ANGSTROMS) OF 36-382 IN COMPLEX WITH NGF,
RP   HOMODIMERIZATION, SUBUNIT, SUBCELLULAR LOCATION, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-95; ASN-121; ASN-188; ASN-262; ASN-281 AND
RP   ASN-358.
RX   PubMed=17196528; DOI=10.1016/j.neuron.2006.09.034;
RA   Wehrman T., He X., Raab B., Dukipatti A., Blau H., Garcia K.C.;
RT   "Structural and mechanistic insights into nerve growth factor
RT   interactions with the TrkA and p75 receptors.";
RL   Neuron 53:25-38(2007).
RN   [25]
RP   VARIANT CIPA ARG-577.
RX   PubMed=8696348; DOI=10.1038/ng0896-485;
RA   Indo Y., Tsuruta M., Hayashida Y., Karim M.A., Ohta K., Kawano T.,
RA   Mitsubuchi H., Tonoki H., Awaya Y., Matsuda I.;
RT   "Mutations in the TRKA/NGF receptor gene in patients with congenital
RT   insensitivity to pain with anhidrosis.";
RL   Nat. Genet. 13:485-488(1996).
RN   [26]
RP   VARIANT CIPA PRO-780.
RX   PubMed=10090906; DOI=10.1086/302319;
RA   Greco A., Villa R., Tubino B., Romano L., Penso D., Pierotti M.A.;
RT   "A novel NTRK1 mutation associated with congenital insensitivity to
RT   pain with anhidrosis.";
RL   Am. J. Hum. Genet. 64:1207-1210(1999).
RN   [27]
RP   VARIANTS CIPA PRO-213; TRP-649 AND SER-714, AND VARIANTS SER-85;
RP   TYR-604 AND VAL-613.
RX   PubMed=10330344; DOI=10.1086/302422;
RA   Mardy S., Miura Y., Endo F., Matsuda I., Sztriha L., Frossard P.,
RA   Moosa A., Ismail E.A.R., Macaya A., Andria G., Toscano E., Gibson W.,
RA   Graham G.E., Indo Y.;
RT   "Congenital insensitivity to pain with anhidrosis: novel mutations in
RT   the TRKA (NTRK1) gene encoding a high-affinity receptor for nerve
RT   growth factor.";
RL   Am. J. Hum. Genet. 64:1570-1579(1999).
RN   [28]
RP   VARIANTS TYR-604; VAL-613 AND GLN-780.
RX   PubMed=10443680; DOI=10.1210/jcem.84.8.5901;
RA   Gimm O., Greco A., Hoang-Vu C., Dralle H., Pierotti M.A., Eng C.;
RT   "Mutation analysis reveals novel sequence variants in NTRK1 in
RT   sporadic human medullary thyroid carcinoma.";
RL   J. Clin. Endocrinol. Metab. 84:2784-2787(1999).
RN   [29]
RP   VARIANT CIPA VAL-587.
RX   PubMed=10233776; DOI=10.1046/j.1523-1747.1999.00569.x;
RA   Yotsumoto S., Setoyama M., Hozumi H., Mizoguchi S., Fukumaru S.,
RA   Kobayashi K., Saheki T., Kanzaki T.;
RT   "A novel point mutation affecting the tyrosine kinase domain of the
RT   TRKA gene in a family with congenital insensitivity to pain with
RT   anhidrosis.";
RL   J. Invest. Dermatol. 112:810-814(1999).
RN   [30]
RP   VARIANTS TYR-604 AND VAL-613.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [31]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [32]
RP   VARIANT CIPA LEU-695, AND VARIANT VAL-613.
RC   TISSUE=Peripheral blood;
RX   PubMed=10861667;
RX   DOI=10.1002/1096-8628(20000619)92:5<353::AID-AJMG12>3.0.CO;2-C;
RA   Shatzky S., Moses S., Levy J., Pinsk V., Hershkovitz E., Herzog L.,
RA   Shorer Z., Luder A., Parvari R.;
RT   "Congenital insensitivity to pain with anhidrosis (CIPA) in Israeli-
RT   Bedouins: genetic heterogeneity, novel mutations in the TRKA/NGF
RT   receptor gene, clinical findings, and results of nerve conduction
RT   studies.";
RL   Am. J. Med. Genet. 92:353-360(2000).
RN   [33]
RP   VARIANTS CIPA PRO-93; ARG-522; ARG-577; CYS-654 AND TYR-674.
RX   PubMed=10982191; DOI=10.1007/s004390051018;
RA   Miura Y., Mardy S., Awaya Y., Nihei K., Endo F., Matsuda I., Indo Y.;
RT   "Mutation and polymorphism analysis of the TRKA (NTRK1) gene encoding
RT   a high-affinity receptor for nerve growth factor in congenital
RT   insensitivity to pain with anhidrosis (CIPA) families.";
RL   Hum. Genet. 106:116-124(2000).
RN   [34]
RP   VARIANT CIPA ARG-577.
RX   PubMed=10567924;
RX   DOI=10.1002/(SICI)1097-4652(200001)182:1<127::AID-JCP14>3.0.CO;2-0;
RA   Greco A., Villa R., Fusetti L., Orlandi R., Pierotti M.A.;
RT   "The Gly571Arg mutation, associated with the autonomic and sensory
RT   disorder congenital insensitivity to pain with anhidrosis, causes the
RT   inactivation of the NTRK1/nerve growth factor receptor.";
RL   J. Cell. Physiol. 182:127-133(2000).
RN   [35]
RP   VARIANT CIPA CYS-359, AND VARIANTS TYR-604 AND VAL-613.
RX   PubMed=11310631; DOI=10.1002/ana.103;
RA   Houlden H., King R.H., Hashemi-Nejad A., Wood N.W., Mathias C.J.,
RA   Reilly M., Thomas P.K.;
RT   "A novel TRK A (NTRK1) mutation associated with hereditary sensory and
RT   autonomic neuropathy type V.";
RL   Ann. Neurol. 49:521-525(2001).
RN   [36]
RP   CHARACTERIZATION OF VARIANTS CIPA PRO-93; PRO-213; ARG-522; ARG-577;
RP   TRP-649; CYS-654 AND SER-714, AND CHARACTERIZATION OF VARIANTS SER-85;
RP   TYR-604; VAL-613 AND TYR-674.
RX   PubMed=11159935; DOI=10.1093/hmg/10.3.179;
RA   Mardy S., Miura Y., Endo F., Matsuda I., Indo Y.;
RT   "Congenital insensitivity to pain with anhidrosis (CIPA): effect of
RT   TRKA (NTRK1) missense mutations on autophosphorylation of the receptor
RT   tyrosine kinase for nerve growth factor.";
RL   Hum. Mol. Genet. 10:179-188(2001).
RN   [37]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-80; VAL-107; MET-237; GLY-238;
RP   GLY-260; GLN-444; CYS-452; THR-566; TYR-604; VAL-613; GLN-780 AND
RP   ILE-790.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [38]
RP   VARIANTS CIPA SER-572 AND ARG-717.
RX   PubMed=18077166; DOI=10.1016/j.nmd.2007.10.005;
RA   Huehne K., Zweier C., Raab K., Odent S., Bonnaure-Mallet M.,
RA   Sixou J.L., Landrieu P., Goizet C., Sarlangue J., Baumann M.,
RA   Eggermann T., Rauch A., Ruppert S., Stettner G.M., Rautenstrauss B.;
RT   "Novel missense, insertion and deletion mutations in the neurotrophic
RT   tyrosine kinase receptor type 1 gene (NTRK1) associated with
RT   congenital insensitivity to pain with anhidrosis.";
RL   Neuromuscul. Disord. 18:159-166(2008).
RN   [39]
RP   VARIANTS CIPA LYS-492 AND CYS-654, AND VARIANT TRP-6.
RX   PubMed=22302274; DOI=10.1007/s00415-011-6397-y;
RA   Davidson G.L., Murphy S.M., Polke J.M., Laura M., Salih M.A.,
RA   Muntoni F., Blake J., Brandner S., Davies N., Horvath R., Price S.,
RA   Donaghy M., Roberts M., Foulds N., Ramdharry G., Soler D., Lunn M.P.,
RA   Manji H., Davis M.B., Houlden H., Reilly M.M.;
RT   "Frequency of mutations in the genes associated with hereditary
RT   sensory and autonomic neuropathy in a UK cohort.";
RL   J. Neurol. 259:1673-1685(2012).
RN   [40]
RP   VARIANTS CIPA GLU-517; GLU-522; PRO-657; THR-699; SER-752; SER-763 AND
RP   CYS-771, CHARACTERIZATION OF VARIANTS CIPA GLU-517; GLU-522; PRO-657;
RP   THR-699; SER-752; SER-763 AND CYS-771, GLYCOSYLATION, SUBCELLULAR
RP   LOCATION, AUTOPHOSPHORYLATION AFTER NGF STIMULATION, AND FUNCTION.
RX   PubMed=27676246; DOI=10.1002/humu.23123;
RA   Shaikh S.S., Chen Y.C., Halsall S.A., Nahorski M.S., Omoto K.,
RA   Young G.T., Phelan A., Woods C.G.;
RT   "A comprehensive functional analysis of NTRK1 missense mutations
RT   causing hereditary sensory and autonomic neuropathy type IV (HSAN
RT   IV).";
RL   Hum. Mutat. 38:55-63(2017).
CC   -!- FUNCTION: Receptor tyrosine kinase involved in the development and
CC       the maturation of the central and peripheral nervous systems
CC       through regulation of proliferation, differentiation and survival
CC       of sympathetic and nervous neurons. High affinity receptor for NGF
CC       which is its primary ligand (PubMed:1850821, PubMed:1849459,
CC       PubMed:1281417, PubMed:8325889, PubMed:15488758, PubMed:17196528).
CC       Can also bind and be activated by NTF3/neurotrophin-3. However,
CC       NTF3 only supports axonal extension through NTRK1 but has no
CC       effect on neuron survival (By similarity). Upon dimeric NGF
CC       ligand-binding, undergoes homodimerization, autophosphorylation
CC       and activation (PubMed:1281417). Recruits, phosphorylates and/or
CC       activates several downstream effectors including SHC1, FRS2,
CC       SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping
CC       signaling cascades driving cell survival and differentiation.
CC       Through SHC1 and FRS2 activates a GRB2-Ras-MAPK cascade that
CC       regulates cell differentiation and survival. Through PLCG1
CC       controls NF-Kappa-B activation and the transcription of genes
CC       involved in cell survival. Through SHC1 and SH2B1 controls a Ras-
CC       PI3 kinase-AKT1 signaling cascade that is also regulating
CC       survival. In absence of ligand and activation, may promote cell
CC       death, making the survival of neurons dependent on trophic
CC       factors. {ECO:0000250|UniProtKB:P35739,
CC       ECO:0000250|UniProtKB:Q3UFB7, ECO:0000269|PubMed:11244088,
CC       ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:17196528, ECO:0000269|PubMed:1849459,
CC       ECO:0000269|PubMed:1850821, ECO:0000269|PubMed:27676246,
CC       ECO:0000269|PubMed:8155326, ECO:0000269|PubMed:8325889}.
CC   -!- FUNCTION: Isoform TrkA-III: Resistant to NGF, it constitutively
CC       activates AKT1 and NF-kappa-B and is unable to activate the Ras-
CC       MAPK signaling cascade. Antagonizes the anti-proliferative NGF-
CC       NTRK1 signaling that promotes neuronal precursors differentiation.
CC       Isoform TrkA-III promotes angiogenesis and has oncogenic activity
CC       when overexpressed. {ECO:0000269|PubMed:15488758}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:1281417,
CC       ECO:0000269|PubMed:2927393}.
CC   -!- ENZYME REGULATION: The pro-survival signaling effect of NTRK1 in
CC       neurons requires its endocytosis into signaling early endosomes
CC       and its retrograde axonal transport. This is regulated by
CC       different proteins including CFL1, RAC1 and SORT1. NTF3 is unable
CC       to induce this signaling probably due to the lability of the NTF3-
CC       NTRK1 complex in endosomes. SH2D1A inhibits the
CC       autophosphorylation of the receptor, and alters the recruitment
CC       and activation of downstream effectors and signaling cascades (By
CC       similarity). Regulated by NGFR (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:Q3UFB7}.
CC   -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low
CC       affinity) and dimeric (high affinity) structures. Homodimerization
CC       is induced by binding of a NGF dimer (PubMed:1281417,
CC       PubMed:10490030, PubMed:17196528). Interacts with SQSTM1; bridges
CC       NTRK1 to NGFR (PubMed:11244088). Forms a ternary complex with NGFR
CC       and KIDINS220; this complex is affected by the expression levels
CC       of KIDINS220 and an increase in KIDINS220 expression leads to a
CC       decreased association of NGFR and NTRK1 (By similarity). Interacts
CC       with SH2D1A; regulates NTRK1 (By similarity). Interacts
CC       (phosphorylated upon activation by NGF) with SHC1; mediates SHC1
CC       phosphorylation and activation (PubMed:8155326, PubMed:15488758).
CC       Interacts (phosphorylated upon activation by NGF) with PLCG1;
CC       mediates PLCG1 phosphorylation and activation (PubMed:7510697,
CC       PubMed:15488758). Interacts (phosphorylated) with SH2B1 and SH2B2
CC       (By similarity). Interacts with GRB2 (PubMed:15488758). Interacts
CC       with PIK3R1 (PubMed:15488758). Interacts with FRS2
CC       (PubMed:15488758). Interacts with SORT1; may regulate NTRK1
CC       anterograde axonal transport (PubMed:21102451). Interacts with
CC       RAB7A (By similarity). Found in a complex, at least composed of
CC       KIDINS220, MAGI2, NTRK1 and RAPGEF2; the complex is mainly formed
CC       at late endosomes in a nerve growth factor (NGF)-dependent manner
CC       (By similarity). Interacts with RAPGEF2; the interaction is
CC       strengthened after NGF stimulation (By similarity). Interacts with
CC       PTPRS (By similarity). {ECO:0000250, ECO:0000250|UniProtKB:P35739,
CC       ECO:0000269|PubMed:10490030, ECO:0000269|PubMed:11244088,
CC       ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:17196528, ECO:0000269|PubMed:21102451,
CC       ECO:0000269|PubMed:7510697, ECO:0000269|PubMed:8155326,
CC       ECO:0000269|PubMed:8325889}.
CC   -!- INTERACTION:
CC       P22681:CBL; NbExp=2; IntAct=EBI-1028226, EBI-518228;
CC       P01138:NGF; NbExp=2; IntAct=EBI-1028226, EBI-1028250;
CC       Q8K4V6:Pirb (xeno); NbExp=2; IntAct=EBI-1028226, EBI-8602514;
CC       P18031:PTPN1; NbExp=2; IntAct=EBI-1028226, EBI-968788;
CC       Q99523:SORT1; NbExp=3; IntAct=EBI-1028226, EBI-1057058;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1281417,
CC       ECO:0000269|PubMed:15488758, ECO:0000269|PubMed:17196528,
CC       ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:2927393}; Single-
CC       pass type I membrane protein {ECO:0000269|PubMed:1281417,
CC       ECO:0000269|PubMed:15488758}. Early endosome membrane
CC       {ECO:0000250|UniProtKB:P35739}; Single-pass type I membrane
CC       protein {ECO:0000250|UniProtKB:P35739}. Late endosome membrane
CC       {ECO:0000250|UniProtKB:P35739}; Single-pass type I membrane
CC       protein {ECO:0000250|UniProtKB:P35739}. Note=Rapidly internalized
CC       after NGF binding (PubMed:1281417). Internalized to endosomes upon
CC       binding of NGF or NTF3 and further transported to the cell body
CC       via a retrograde axonal transport. Localized at cell membrane and
CC       early endosomes before nerve growth factor (NGF) stimulation.
CC       Recruited to late endosomes after NGF stimulation. Colocalized
CC       with RAPGEF2 at late endosomes. {ECO:0000250|UniProtKB:P35739,
CC       ECO:0000269|PubMed:1281417}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC         Comment=TrkA-I and TrkA-II isoforms have similar biological
CC         properties but are differentially expressed.;
CC       Name=TrkA-II; Synonyms=TrkAII;
CC         IsoId=P04629-1; Sequence=Displayed;
CC         Note=Major isoform.;
CC       Name=TrkA-I; Synonyms=TrkAI;
CC         IsoId=P04629-2; Sequence=VSP_002899;
CC         Note=Has enhanced responsiveness to NTF3 neurotrophin.;
CC       Name=3;
CC         IsoId=P04629-3; Sequence=VSP_041905, VSP_002899;
CC       Name=TrkA-III; Synonyms=TrkAIII;
CC         IsoId=P04629-4; Sequence=VSP_042152, VSP_002899;
CC         Note=Constitutively active. Does not bind NGF and does not
CC         interact with GRB2 and FRS2.;
CC   -!- TISSUE SPECIFICITY: Isoform TrkA-I is found in most non-neuronal
CC       tissues. Isoform TrkA-II is primarily expressed in neuronal cells.
CC       TrkA-III is specifically expressed by pluripotent neural stem and
CC       neural crest progenitors. {ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:8325889}.
CC   -!- INDUCTION: Isoform TrkA-III is up-regulated upon hypoxia in cells
CC       normally expressing it. {ECO:0000269|PubMed:15488758}.
CC   -!- DOMAIN: The transmembrane domain mediates interaction with
CC       KIDINS220. {ECO:0000250}.
CC   -!- DOMAIN: The extracellular domain mediates interaction with NGFR.
CC       {ECO:0000250}.
CC   -!- PTM: Ligand-mediated autophosphorylation (PubMed:2927393,
CC       PubMed:1281417, PubMed:15488758, PubMed:7510697, PubMed:8155326,
CC       PubMed:8325889, PubMed:27676246). Interaction with SQSTM1 is
CC       phosphotyrosine-dependent. Autophosphorylation at Tyr-496 mediates
CC       interaction and phosphorylation of SHC1 (PubMed:15488758,
CC       PubMed:7510697, PubMed:8155326, PubMed:8325889).
CC       {ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:2927393,
CC       ECO:0000269|PubMed:7510697, ECO:0000269|PubMed:8155326,
CC       ECO:0000269|PubMed:8325889}.
CC   -!- PTM: N-glycosylated (PubMed:2927393). Isoform TrkA-I and isoform
CC       TrkA-II are N-glycosylated. {ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:17196528, ECO:0000269|PubMed:27676246,
CC       ECO:0000269|PubMed:2927393}.
CC   -!- PTM: Ubiquitinated. Undergoes polyubiquitination upon activation;
CC       regulated by NGFR. Ubiquitination regulates the internalization of
CC       the receptor. {ECO:0000250|UniProtKB:Q3UFB7}.
CC   -!- DISEASE: Congenital insensitivity to pain with anhidrosis (CIPA)
CC       [MIM:256800]: Characterized by a congenital insensitivity to pain,
CC       anhidrosis (absence of sweating), absence of reaction to noxious
CC       stimuli, self-mutilating behavior, and mental retardation. This
CC       rare autosomal recessive disorder is also known as congenital
CC       sensory neuropathy with anhidrosis or hereditary sensory and
CC       autonomic neuropathy type IV or familial dysautonomia type II.
CC       {ECO:0000269|PubMed:10090906, ECO:0000269|PubMed:10233776,
CC       ECO:0000269|PubMed:10330344, ECO:0000269|PubMed:10567924,
CC       ECO:0000269|PubMed:10861667, ECO:0000269|PubMed:10982191,
CC       ECO:0000269|PubMed:11159935, ECO:0000269|PubMed:11310631,
CC       ECO:0000269|PubMed:18077166, ECO:0000269|PubMed:22302274,
CC       ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:8696348}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Note=Chromosomal aberrations involving NTRK1 are found in
CC       papillary thyroid carcinomas (PTCs) (PubMed:2869410,
CC       PubMed:7565764, PubMed:1532241). Translocation t(1;3)(q21;q11)
CC       with TFG generates the TRKT3 (TRK-T3) transcript by fusing TFG to
CC       the 3'-end of NTRK1 (PubMed:7565764). A rearrangement with TPM3
CC       generates the TRK transcript by fusing TPM3 to the 3'-end of NTRK1
CC       (PubMed:2869410). An intrachromosomal rearrangement that links the
CC       protein kinase domain of NTRK1 to the 5'-end of the TPR gene forms
CC       the fusion protein TRK-T1. TRK-T1 is a 55 kDa protein reacting
CC       with antibodies against the C-terminus of the NTRK1 protein
CC       (PubMed:1532241). {ECO:0000269|PubMed:1532241,
CC       ECO:0000269|PubMed:2869410, ECO:0000269|PubMed:7565764}.
CC   -!- MISCELLANEOUS: Trk also stands for tropomyosin-related kinase
CC       since it was first isolated as an oncogenic protein which was the
CC       result of a fusion between the tropomyosin gene TPM3 and NTRK1.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA27243.1; Type=Erroneous termination; Positions=786; Note=Translated as Gln.; Evidence={ECO:0000305};
CC       Sequence=CAA27243.1; Type=Frameshift; Positions=769; Evidence={ECO:0000305};
CC       Sequence=CAA27243.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA29888.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA44719.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA59936.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M23102; AAA36770.1; -; mRNA.
DR   EMBL; AB019488; BAA34355.1; -; Genomic_DNA.
DR   EMBL; AK312704; BAG35582.1; -; mRNA.
DR   EMBL; DB265639; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AL158169; CAH70010.1; -; Genomic_DNA.
DR   EMBL; BC062580; AAH62580.1; -; mRNA.
DR   EMBL; BC136554; AAI36555.1; -; mRNA.
DR   EMBL; BC144239; AAI44240.1; -; mRNA.
DR   EMBL; AY321513; AAP88292.1; -; Genomic_DNA.
DR   EMBL; X03541; CAA27243.1; ALT_SEQ; mRNA.
DR   EMBL; X06704; CAA29888.1; ALT_SEQ; mRNA.
DR   EMBL; X85960; CAA59936.1; ALT_SEQ; mRNA.
DR   EMBL; X62947; CAA44719.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS1161.1; -. [P04629-1]
DR   CCDS; CCDS30890.1; -. [P04629-3]
DR   CCDS; CCDS30891.1; -. [P04629-2]
DR   PIR; A30124; TVHUTT.
DR   PIR; S23741; S23741.
DR   RefSeq; NP_001007793.1; NM_001007792.1. [P04629-3]
DR   RefSeq; NP_001012331.1; NM_001012331.1. [P04629-2]
DR   RefSeq; NP_002520.2; NM_002529.3. [P04629-1]
DR   UniGene; Hs.406293; -.
DR   PDB; 1HE7; X-ray; 2.00 A; A=285-413.
DR   PDB; 1SHC; NMR; -; B=489-500.
DR   PDB; 1WWA; X-ray; 2.50 A; X/Y=278-386.
DR   PDB; 1WWW; X-ray; 2.20 A; X/Y=282-382.
DR   PDB; 2IFG; X-ray; 3.40 A; A/B=36-382.
DR   PDB; 2N90; NMR; -; A/B=410-447.
DR   PDB; 4AOJ; X-ray; 2.75 A; A/B/C=473-796.
DR   PDB; 4CRP; NMR; -; A=282-383.
DR   PDB; 4F0I; X-ray; 2.30 A; A/B=498-796.
DR   PDB; 4GT5; X-ray; 2.40 A; A=498-796.
DR   PDB; 4PMM; X-ray; 2.00 A; A=501-787.
DR   PDB; 4PMP; X-ray; 1.80 A; A=501-787.
DR   PDB; 4PMS; X-ray; 2.80 A; A=501-787.
DR   PDB; 4PMT; X-ray; 2.10 A; A=501-787.
DR   PDB; 4YNE; X-ray; 2.02 A; A=502-796.
DR   PDB; 4YPS; X-ray; 2.10 A; A=502-796.
DR   PDB; 5H3Q; X-ray; 2.10 A; A=473-796.
DR   PDB; 5JFS; X-ray; 2.07 A; A=502-796.
DR   PDB; 5JFV; X-ray; 1.59 A; A=502-796.
DR   PDB; 5JFW; X-ray; 1.52 A; A=502-796.
DR   PDB; 5JFX; X-ray; 1.63 A; A=502-796.
DR   PDB; 5KMI; X-ray; 1.87 A; A=474-796.
DR   PDB; 5KMJ; X-ray; 2.04 A; A=474-796.
DR   PDB; 5KMK; X-ray; 2.24 A; A=474-796.
DR   PDB; 5KML; X-ray; 2.01 A; A=474-796.
DR   PDB; 5KMM; X-ray; 2.12 A; A=474-796.
DR   PDB; 5KMN; X-ray; 2.14 A; A=474-796.
DR   PDB; 5KMO; X-ray; 2.67 A; A=474-796.
DR   PDBsum; 1HE7; -.
DR   PDBsum; 1SHC; -.
DR   PDBsum; 1WWA; -.
DR   PDBsum; 1WWW; -.
DR   PDBsum; 2IFG; -.
DR   PDBsum; 2N90; -.
DR   PDBsum; 4AOJ; -.
DR   PDBsum; 4CRP; -.
DR   PDBsum; 4F0I; -.
DR   PDBsum; 4GT5; -.
DR   PDBsum; 4PMM; -.
DR   PDBsum; 4PMP; -.
DR   PDBsum; 4PMS; -.
DR   PDBsum; 4PMT; -.
DR   PDBsum; 4YNE; -.
DR   PDBsum; 4YPS; -.
DR   PDBsum; 5H3Q; -.
DR   PDBsum; 5JFS; -.
DR   PDBsum; 5JFV; -.
DR   PDBsum; 5JFW; -.
DR   PDBsum; 5JFX; -.
DR   PDBsum; 5KMI; -.
DR   PDBsum; 5KMJ; -.
DR   PDBsum; 5KMK; -.
DR   PDBsum; 5KML; -.
DR   PDBsum; 5KMM; -.
DR   PDBsum; 5KMN; -.
DR   PDBsum; 5KMO; -.
DR   ProteinModelPortal; P04629; -.
DR   SMR; P04629; -.
DR   BioGrid; 110969; 1942.
DR   DIP; DIP-5714N; -.
DR   IntAct; P04629; 17.
DR   MINT; MINT-124106; -.
DR   STRING; 9606.ENSP00000431418; -.
DR   BindingDB; P04629; -.
DR   ChEMBL; CHEMBL2815; -.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   GuidetoPHARMACOLOGY; 1817; -.
DR   iPTMnet; P04629; -.
DR   PhosphoSitePlus; P04629; -.
DR   BioMuta; NTRK1; -.
DR   DMDM; 94730402; -.
DR   PaxDb; P04629; -.
DR   PeptideAtlas; P04629; -.
DR   PRIDE; P04629; -.
DR   Ensembl; ENST00000368196; ENSP00000357179; ENSG00000198400. [P04629-2]
DR   Ensembl; ENST00000392302; ENSP00000376120; ENSG00000198400. [P04629-3]
DR   Ensembl; ENST00000524377; ENSP00000431418; ENSG00000198400. [P04629-1]
DR   GeneID; 4914; -.
DR   KEGG; hsa:4914; -.
DR   UCSC; uc001fqf.2; human. [P04629-1]
DR   CTD; 4914; -.
DR   DisGeNET; 4914; -.
DR   GeneCards; NTRK1; -.
DR   GeneReviews; NTRK1; -.
DR   HGNC; HGNC:8031; NTRK1.
DR   HPA; CAB004606; -.
DR   HPA; HPA035799; -.
DR   HPA; HPA076570; -.
DR   MalaCards; NTRK1; -.
DR   MIM; 164970; gene.
DR   MIM; 191315; gene.
DR   MIM; 256800; phenotype.
DR   neXtProt; NX_P04629; -.
DR   OpenTargets; ENSG00000198400; -.
DR   Orphanet; 99361; Familial medullary thyroid carcinoma.
DR   Orphanet; 642; Hereditary sensory and autonomic neuropathy type 4.
DR   Orphanet; 64752; Hereditary sensory and autonomic neuropathy type 5.
DR   Orphanet; 146; Papillary or follicular thyroid carcinoma.
DR   PharmGKB; PA31817; -.
DR   eggNOG; ENOG410IMMI; Eukaryota.
DR   eggNOG; ENOG410XTGG; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOVERGEN; HBG056735; -.
DR   InParanoid; P04629; -.
DR   KO; K03176; -.
DR   OMA; KNVTCWA; -.
DR   OrthoDB; EOG091G01JY; -.
DR   PhylomeDB; P04629; -.
DR   TreeFam; TF106465; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-167021; PLC-gamma1 signalling.
DR   Reactome; R-HSA-167044; Signalling to RAS.
DR   Reactome; R-HSA-170968; Frs2-mediated activation.
DR   Reactome; R-HSA-170984; ARMS-mediated activation.
DR   Reactome; R-HSA-177504; Retrograde neurotrophin signalling.
DR   Reactome; R-HSA-187024; NGF-independant TRKA activation.
DR   Reactome; R-HSA-187042; TRKA activation by NGF.
DR   Reactome; R-HSA-187706; Signalling to p38 via RIT and RIN.
DR   Reactome; R-HSA-198203; PI3K/AKT activation.
DR   Reactome; R-HSA-198745; Signalling to STAT3.
DR   SignaLink; P04629; -.
DR   SIGNOR; P04629; -.
DR   ChiTaRS; NTRK1; human.
DR   EvolutionaryTrace; P04629; -.
DR   GenomeRNAi; 4914; -.
DR   PRO; PR:P04629; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000198400; -.
DR   ExpressionAtlas; P04629; baseline and differential.
DR   Genevisible; P04629; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005769; C:early endosome; ISS:UniProtKB.
DR   GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005768; C:endosome; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005770; C:late endosome; ISS:UniProtKB.
DR   GO; GO:0031902; C:late endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0043234; C:protein complex; ISS:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005004; F:GPI-linked ephrin receptor activity; IEA:Ensembl.
DR   GO; GO:0019900; F:kinase binding; IEA:Ensembl.
DR   GO; GO:0048406; F:nerve growth factor binding; IDA:UniProtKB.
DR   GO; GO:0010465; F:nerve growth factor receptor activity; IDA:UniProtKB.
DR   GO; GO:0043121; F:neurotrophin binding; TAS:ProtInc.
DR   GO; GO:0005166; F:neurotrophin p75 receptor binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0060385; P:axonogenesis involved in innervation; ISS:UniProtKB.
DR   GO; GO:0030183; P:B cell differentiation; IEA:Ensembl.
DR   GO; GO:0061368; P:behavioral response to formalin induced pain; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IMP:UniProtKB.
DR   GO; GO:0071316; P:cellular response to nicotine; IEA:Ensembl.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0050966; P:detection of mechanical stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0007611; P:learning or memory; IEA:Ensembl.
DR   GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl.
DR   GO; GO:0007018; P:microtubule-based movement; TAS:Reactome.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0038180; P:nerve growth factor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0021553; P:olfactory nerve development; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IDA:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0043068; P:positive regulation of programmed cell death; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:BHF-UCL.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0010623; P:programmed cell death involved in cell development; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0048678; P:response to axon injury; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0051602; P:response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0051599; P:response to hydrostatic pressure; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0009314; P:response to radiation; IEA:Ensembl.
DR   GO; GO:0060009; P:Sertoli cell development; IEA:Ensembl.
DR   GO; GO:0048485; P:sympathetic nervous system development; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR031635; NTRK_C2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR020461; Tyr_kinase_neurotrophic_rcpt_1.
DR   InterPro; IPR020777; Tyr_kinase_NGF_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF13855; LRR_8; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF16920; TPKR_C2; 1.
DR   PRINTS; PR01939; NTKRECEPTOR.
DR   PRINTS; PR01940; NTKRECEPTOR1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF52058; SSF52058; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Chromosomal rearrangement; Complete proteome; Developmental protein;
KW   Differentiation; Disease mutation; Disulfide bond; Endosome;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Leucine-rich repeat;
KW   Membrane; Neurogenesis; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     32       {ECO:0000255}.
FT   CHAIN        33    796       High affinity nerve growth factor
FT                                receptor.
FT                                /FTId=PRO_0000016724.
FT   TOPO_DOM     33    423       Extracellular. {ECO:0000255}.
FT   TRANSMEM    424    439       Helical. {ECO:0000255}.
FT   TOPO_DOM    440    796       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       90    113       LRR 1.
FT   REPEAT      116    137       LRR 2.
FT   DOMAIN      148    193       LRRCT.
FT   DOMAIN      194    283       Ig-like C2-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00114}.
FT   DOMAIN      299    365       Ig-like C2-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00114}.
FT   DOMAIN      510    781       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     516    524       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      469    490       Interaction with SQSTM1. {ECO:0000250}.
FT   ACT_SITE    650    650       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     544    544       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        398    399       Breakpoint for translocation to form TRK
FT                                and TRK-T3.
FT   SITE        486    486       Breakpoint for translocation to form TRK-
FT                                T1.
FT   SITE        496    496       Interaction with SHC1.
FT   SITE        791    791       Interaction with PLCG1.
FT   MOD_RES     496    496       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15488758,
FT                                ECO:0000269|PubMed:27676246,
FT                                ECO:0000269|PubMed:8155326}.
FT   MOD_RES     676    676       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:8325889}.
FT   MOD_RES     680    680       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15488758}.
FT   MOD_RES     681    681       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15488758}.
FT   MOD_RES     791    791       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15488758,
FT                                ECO:0000269|PubMed:7510697,
FT                                ECO:0000269|PubMed:8155326}.
FT   CARBOHYD     67     67       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     95     95       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    121    121       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    188    188       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:2IFG,
FT                                ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    202    202       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    253    253       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    262    262       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:2IFG,
FT                                ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    281    281       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:2IFG,
FT                                ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    318    318       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    323    323       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    338    338       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    358    358       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:2IFG,
FT                                ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    401    401       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     36     41       {ECO:0000244|PDB:2IFG}.
FT   DISULFID     40     50       {ECO:0000244|PDB:2IFG}.
FT   DISULFID    154    191       {ECO:0000244|PDB:2IFG,
FT                                ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17196528}.
FT   DISULFID    215    265       {ECO:0000244|PDB:2IFG,
FT                                ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17196528}.
FT   DISULFID    300    345       {ECO:0000244|PDB:1HE7,
FT                                ECO:0000244|PDB:1WWA,
FT                                ECO:0000244|PDB:1WWW,
FT                                ECO:0000244|PDB:2IFG,
FT                                ECO:0000244|PDB:4CRP}.
FT   VAR_SEQ       1     71       MLRGGRRGQLGWHSWAAGPGSLLAWLILASAGAAPCPDACC
FT                                PHGSSGLRCTRDGALDSLHHLPGAENLTEL -> MKEAALI
FT                                CLAPSVPPILTVKSWDTMQLRAARSRCTNLLAAS (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041905.
FT   VAR_SEQ     192    284       GVPTLKVQVPNASVDVGDDVLLRCQVEGRGLEQAGWILTEL
FT                                EQSATVMKSGGLPSLGLTLANVTSDLNRKNVTCWAENDVGR
FT                                AEVSVQVNVSF -> V (in isoform TrkA-III).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_042152.
FT   VAR_SEQ     393    398       Missing (in isoform TrkA-I, isoform 3 and
FT                                isoform TrkA-III).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:2927393}.
FT                                /FTId=VSP_002899.
FT   VARIANT       6      6       R -> W (in dbSNP:rs201472270).
FT                                {ECO:0000269|PubMed:22302274}.
FT                                /FTId=VAR_068480.
FT   VARIANT      18     18       G -> E (in dbSNP:rs1007211).
FT                                /FTId=VAR_049714.
FT   VARIANT      80     80       Q -> R (in dbSNP:rs55891455).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041461.
FT   VARIANT      85     85       R -> S (in dbSNP:rs543320028).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009623.
FT   VARIANT      93     93       L -> P (in CIPA; aberrantly processed;
FT                                shows diminished autophosphorylation in
FT                                neuronal cells).
FT                                {ECO:0000269|PubMed:10982191,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009624.
FT   VARIANT     107    107       A -> V (in an ovarian serous carcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs540521894).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041462.
FT   VARIANT     213    213       L -> P (in CIPA; aberrantly processed;
FT                                shows diminished autophosphorylation in
FT                                neuronal cells; dbSNP:rs747711259).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009625.
FT   VARIANT     237    237       T -> M (in dbSNP:rs55909005).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041463.
FT   VARIANT     238    238       V -> G (in dbSNP:rs56000394).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041464.
FT   VARIANT     260    260       R -> G (in dbSNP:rs35116695).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041465.
FT   VARIANT     359    359       Y -> C (in CIPA; dbSNP:rs121964869).
FT                                {ECO:0000269|PubMed:11310631}.
FT                                /FTId=VAR_068481.
FT   VARIANT     444    444       R -> Q (in dbSNP:rs56320207).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041466.
FT   VARIANT     452    452       R -> C (in dbSNP:rs34900547).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041467.
FT   VARIANT     492    492       E -> K (in CIPA; dbSNP:rs144901788).
FT                                {ECO:0000269|PubMed:22302274}.
FT                                /FTId=VAR_068482.
FT   VARIANT     517    517       G -> E (in CIPA; following transfection
FT                                in neuroblastoma cells and NGF treatment,
FT                                small decrease in the percentage of cells
FT                                differentiated into neuronal phenotype,
FT                                but in differentiated cells, the average
FT                                neurite length is comparable to wild-
FT                                type; no effect on N-glycosylation,
FT                                subcellular location, nor on basal and
FT                                NGF-induced autophosphorylation; loss of
FT                                NGF-stimulated calcium flux;
FT                                dbSNP:rs606231467).
FT                                {ECO:0000269|PubMed:27676246}.
FT                                /FTId=VAR_077472.
FT   VARIANT     522    522       G -> E (in CIPA; no effect on N-
FT                                glycosylation, nor on subcellular
FT                                location; reduced basal
FT                                autophosphorylation and complete loss of
FT                                NGF-induced autophosphorylation; loss of
FT                                NGF-stimulated calcium flux).
FT                                {ECO:0000269|PubMed:27676246}.
FT                                /FTId=VAR_077473.
FT   VARIANT     522    522       G -> R (in CIPA; processed as wild-type
FT                                but shows significantly diminished
FT                                autophosphorylation in both neuronal and
FT                                non-neuronal cells).
FT                                {ECO:0000269|PubMed:10982191,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009626.
FT   VARIANT     566    566       M -> T (in dbSNP:rs55892037).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041468.
FT   VARIANT     572    572       I -> S (in CIPA).
FT                                {ECO:0000269|PubMed:18077166}.
FT                                /FTId=VAR_077474.
FT   VARIANT     577    577       G -> R (in CIPA; loss of function;
FT                                processed as wild-type but shows
FT                                significantly diminished
FT                                autophosphorylation in both neuronal and
FT                                non-neuronal cells; dbSNP:rs121964866).
FT                                {ECO:0000269|PubMed:10567924,
FT                                ECO:0000269|PubMed:10982191,
FT                                ECO:0000269|PubMed:11159935,
FT                                ECO:0000269|PubMed:8696348}.
FT                                /FTId=VAR_004103.
FT   VARIANT     587    587       M -> V (in CIPA; dbSNP:rs121964870).
FT                                {ECO:0000269|PubMed:10233776}.
FT                                /FTId=VAR_009627.
FT   VARIANT     604    604       H -> Y (in dbSNP:rs6336).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10443680,
FT                                ECO:0000269|PubMed:11159935,
FT                                ECO:0000269|PubMed:11310631,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_009628.
FT   VARIANT     613    613       G -> V (in dbSNP:rs6339).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10443680,
FT                                ECO:0000269|PubMed:10861667,
FT                                ECO:0000269|PubMed:11159935,
FT                                ECO:0000269|PubMed:11310631,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_009629.
FT   VARIANT     649    649       R -> W (in CIPA; processed as wild-type
FT                                but shows significantly diminished
FT                                autophosphorylation in both neuronal and
FT                                non-neuronal cells; dbSNP:rs369353892).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009630.
FT   VARIANT     654    654       R -> C (in CIPA; processed as wild-type
FT                                but shows significantly diminished
FT                                autophosphorylation in both neuronal and
FT                                non-neuronal cells; dbSNP:rs764992664).
FT                                {ECO:0000269|PubMed:10982191,
FT                                ECO:0000269|PubMed:11159935,
FT                                ECO:0000269|PubMed:22302274}.
FT                                /FTId=VAR_009631.
FT   VARIANT     657    657       L -> P (in CIPA; following transfection
FT                                in neuroblastoma cells and NGF treatment,
FT                                loss of differentiation into neuronal
FT                                phenotype; partially decreased N-
FT                                glycosylation; reduced expression at the
FT                                plasma membrane; reduced basal
FT                                autophosphorylation and complete loss of
FT                                NGF-induced autophosphorylation; loss of
FT                                NGF-stimulated calcium flux).
FT                                {ECO:0000269|PubMed:27676246}.
FT                                /FTId=VAR_077475.
FT   VARIANT     674    674       D -> Y (in CIPA; unknown pathological
FT                                significance; might impair the function
FT                                of the enzyme without compromising
FT                                autophosphorylation; dbSNP:rs80356677).
FT                                {ECO:0000269|PubMed:10982191,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009632.
FT   VARIANT     695    695       P -> L (in CIPA; dbSNP:rs121964868).
FT                                {ECO:0000269|PubMed:10861667}.
FT                                /FTId=VAR_009633.
FT   VARIANT     699    699       I -> T (in CIPA; partially decreased N-
FT                                glycosylation; reduced expression at the
FT                                plasma membrane; reduced basal
FT                                autophosphorylation and complete loss of
FT                                NGF-induced autophosphorylation; loss of
FT                                NGF-stimulated calcium flux).
FT                                {ECO:0000269|PubMed:27676246}.
FT                                /FTId=VAR_077476.
FT   VARIANT     714    714       G -> S (in CIPA; processed as wild-type
FT                                but shows significantly diminished
FT                                autophosphorylation in both neuronal and
FT                                non-neuronal cells; dbSNP:rs770727871).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009634.
FT   VARIANT     717    717       L -> R (in CIPA; found in a compound
FT                                heterozygote also carrying an premature
FT                                stop codon at position 558).
FT                                {ECO:0000269|PubMed:18077166}.
FT                                /FTId=VAR_077477.
FT   VARIANT     752    752       C -> S (in CIPA; unknown pathological
FT                                significance; following transfection in
FT                                neuroblastoma cells and NGF treatment, no
FT                                effect on neurite outgrowth, nor neurite
FT                                length; no effect on N-glycosylation,
FT                                subcellular location, basal and NGF-
FT                                induced autophosphorylation, nor on NGF-
FT                                stimulated calcium flux).
FT                                {ECO:0000269|PubMed:27676246}.
FT                                /FTId=VAR_077478.
FT   VARIANT     763    763       C -> S (in CIPA; following transfection
FT                                in neuroblastoma cells and NGF treatment,
FT                                decreased percentage of cells
FT                                differentiated into neuronal phenotype
FT                                and reduced neurite length compared with
FT                                wild-type; slightly decreased N-
FT                                glycosylation; reduced expression at the
FT                                plasma membrane; reduced basal and NGF-
FT                                induced autophosphorylation; small
FT                                reduction in NGF-stimulated calcium
FT                                flux). {ECO:0000269|PubMed:27676246}.
FT                                /FTId=VAR_077479.
FT   VARIANT     771    771       R -> C (in CIPA; partially decreased N-
FT                                glycosylation; reduced expression at the
FT                                plasma membrane; reduced basal
FT                                autophosphorylation and complete loss of
FT                                NGF-induced autophosphorylation; loss of
FT                                NGF-stimulated calcium flux).
FT                                {ECO:0000269|PubMed:27676246}.
FT                                /FTId=VAR_077480.
FT   VARIANT     780    780       R -> P (in CIPA; loss of function;
FT                                dbSNP:rs35669708).
FT                                {ECO:0000269|PubMed:10090906}.
FT                                /FTId=VAR_009635.
FT   VARIANT     780    780       R -> Q (in dbSNP:rs35669708).
FT                                {ECO:0000269|PubMed:10443680,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_009636.
FT   VARIANT     790    790       V -> I (in dbSNP:rs55948542).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041469.
FT   MUTAGEN     496    496       Y->F: Loss of interaction with SHC1 and
FT                                altered phosphorylation of SHC1. Altered
FT                                neurite outgrowth and altered activation
FT                                of the MAPK pathway; when associated with
FT                                F-791. {ECO:0000269|PubMed:8155326}.
FT   MUTAGEN     544    544       K->N: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:1281417,
FT                                ECO:0000269|PubMed:8155326}.
FT   MUTAGEN     791    791       Y->F: Loss of interaction with PLCG1 and
FT                                altered phosphorylation of PLCG1. Altered
FT                                neurite outgrowth and altered activation
FT                                of the MAPK pathway; when associated with
FT                                F-496. {ECO:0000269|PubMed:7510697,
FT                                ECO:0000269|PubMed:8155326}.
FT   CONFLICT    263    263       V -> L (in Ref. 1; AAA36770).
FT                                {ECO:0000305}.
FT   CONFLICT    300    300       C -> S (in Ref. 1; AAA36770).
FT                                {ECO:0000305}.
FT   CONFLICT    529    529       C -> S (in Ref. 10; CAA59936).
FT                                {ECO:0000305}.
FT   STRAND       38     40       {ECO:0000244|PDB:2IFG}.
FT   STRAND       43     46       {ECO:0000244|PDB:2IFG}.
FT   TURN         57     61       {ECO:0000244|PDB:2IFG}.
FT   STRAND       69     72       {ECO:0000244|PDB:2IFG}.
FT   HELIX        84     86       {ECO:0000244|PDB:2IFG}.
FT   STRAND       94     97       {ECO:0000244|PDB:2IFG}.
FT   HELIX       110    112       {ECO:0000244|PDB:2IFG}.
FT   STRAND      119    121       {ECO:0000244|PDB:2IFG}.
FT   TURN        133    135       {ECO:0000244|PDB:2IFG}.
FT   STRAND      142    144       {ECO:0000244|PDB:2IFG}.
FT   HELIX       154    156       {ECO:0000244|PDB:2IFG}.
FT   HELIX       157    164       {ECO:0000244|PDB:2IFG}.
FT   HELIX       171    173       {ECO:0000244|PDB:2IFG}.
FT   STRAND      178    181       {ECO:0000244|PDB:2IFG}.
FT   STRAND      195    199       {ECO:0000244|PDB:2IFG}.
FT   STRAND      211    218       {ECO:0000244|PDB:2IFG}.
FT   STRAND      227    230       {ECO:0000244|PDB:2IFG}.
FT   STRAND      234    238       {ECO:0000244|PDB:2IFG}.
FT   STRAND      244    253       {ECO:0000244|PDB:2IFG}.
FT   TURN        257    260       {ECO:0000244|PDB:2IFG}.
FT   STRAND      263    265       {ECO:0000244|PDB:2IFG}.
FT   STRAND      276    278       {ECO:0000244|PDB:2IFG}.
FT   STRAND      284    290       {ECO:0000244|PDB:1WWW}.
FT   STRAND      298    305       {ECO:0000244|PDB:1HE7}.
FT   STRAND      312    317       {ECO:0000244|PDB:1HE7}.
FT   STRAND      326    333       {ECO:0000244|PDB:1HE7}.
FT   STRAND      342    350       {ECO:0000244|PDB:1HE7}.
FT   HELIX       353    355       {ECO:0000244|PDB:1HE7}.
FT   STRAND      357    365       {ECO:0000244|PDB:1HE7}.
FT   STRAND      368    376       {ECO:0000244|PDB:1HE7}.
FT   HELIX       418    441       {ECO:0000244|PDB:2N90}.
FT   STRAND      476    478       {ECO:0000244|PDB:5KML}.
FT   HELIX       490    492       {ECO:0000244|PDB:5KMI}.
FT   TURN        494    496       {ECO:0000244|PDB:1SHC}.
FT   HELIX       507    509       {ECO:0000244|PDB:5JFW}.
FT   STRAND      510    517       {ECO:0000244|PDB:5JFW}.
FT   STRAND      520    522       {ECO:0000244|PDB:5JFW}.
FT   STRAND      524    533       {ECO:0000244|PDB:5JFW}.
FT   TURN        534    536       {ECO:0000244|PDB:5KMI}.
FT   STRAND      537    545       {ECO:0000244|PDB:5JFW}.
FT   HELIX       552    566       {ECO:0000244|PDB:5JFW}.
FT   STRAND      575    579       {ECO:0000244|PDB:5JFW}.
FT   STRAND      581    584       {ECO:0000244|PDB:5JFW}.
FT   STRAND      586    590       {ECO:0000244|PDB:5JFW}.
FT   HELIX       597    603       {ECO:0000244|PDB:5JFW}.
FT   STRAND      605    607       {ECO:0000244|PDB:4F0I}.
FT   HELIX       608    611       {ECO:0000244|PDB:4PMP}.
FT   STRAND      615    617       {ECO:0000244|PDB:4YNE}.
FT   STRAND      619    621       {ECO:0000244|PDB:5KMI}.
FT   HELIX       624    643       {ECO:0000244|PDB:5JFW}.
FT   STRAND      646    648       {ECO:0000244|PDB:5KML}.
FT   HELIX       653    655       {ECO:0000244|PDB:5JFW}.
FT   STRAND      656    659       {ECO:0000244|PDB:5JFW}.
FT   HELIX       660    662       {ECO:0000244|PDB:5JFW}.
FT   STRAND      663    666       {ECO:0000244|PDB:5JFW}.
FT   HELIX       672    675       {ECO:0000244|PDB:5KMI}.
FT   HELIX       677    679       {ECO:0000244|PDB:4PMP}.
FT   STRAND      680    683       {ECO:0000244|PDB:5KMI}.
FT   TURN        684    686       {ECO:0000244|PDB:5KMI}.
FT   STRAND      687    689       {ECO:0000244|PDB:5KMI}.
FT   HELIX       691    693       {ECO:0000244|PDB:5JFW}.
FT   HELIX       696    701       {ECO:0000244|PDB:5JFW}.
FT   HELIX       706    721       {ECO:0000244|PDB:5JFW}.
FT   TURN        722    724       {ECO:0000244|PDB:5JFV}.
FT   TURN        727    730       {ECO:0000244|PDB:5JFW}.
FT   HELIX       733    742       {ECO:0000244|PDB:5JFW}.
FT   HELIX       754    763       {ECO:0000244|PDB:5JFW}.
FT   HELIX       768    770       {ECO:0000244|PDB:5JFW}.
FT   HELIX       774    786       {ECO:0000244|PDB:5JFW}.
FT   HELIX       789    793       {ECO:0000244|PDB:5KMI}.
SQ   SEQUENCE   796 AA;  87497 MW;  6C15C721E336B601 CRC64;
     MLRGGRRGQL GWHSWAAGPG SLLAWLILAS AGAAPCPDAC CPHGSSGLRC TRDGALDSLH
     HLPGAENLTE LYIENQQHLQ HLELRDLRGL GELRNLTIVK SGLRFVAPDA FHFTPRLSRL
     NLSFNALESL SWKTVQGLSL QELVLSGNPL HCSCALRWLQ RWEEEGLGGV PEQKLQCHGQ
     GPLAHMPNAS CGVPTLKVQV PNASVDVGDD VLLRCQVEGR GLEQAGWILT ELEQSATVMK
     SGGLPSLGLT LANVTSDLNR KNVTCWAEND VGRAEVSVQV NVSFPASVQL HTAVEMHHWC
     IPFSVDGQPA PSLRWLFNGS VLNETSFIFT EFLEPAANET VRHGCLRLNQ PTHVNNGNYT
     LLAANPFGQA SASIMAAFMD NPFEFNPEDP IPVSFSPVDT NSTSGDPVEK KDETPFGVSV
     AVGLAVFACL FLSTLLLVLN KCGRRNKFGI NRPAVLAPED GLAMSLHFMT LGGSSLSPTE
     GKGSGLQGHI IENPQYFSDA CVHHIKRRDI VLKWELGEGA FGKVFLAECH NLLPEQDKML
     VAVKALKEAS ESARQDFQRE AELLTMLQHQ HIVRFFGVCT EGRPLLMVFE YMRHGDLNRF
     LRSHGPDAKL LAGGEDVAPG PLGLGQLLAV ASQVAAGMVY LAGLHFVHRD LATRNCLVGQ
     GLVVKIGDFG MSRDIYSTDY YRVGGRTMLP IRWMPPESIL YRKFTTESDV WSFGVVLWEI
     FTYGKQPWYQ LSNTEAIDCI TQGRELERPR ACPPEVYAIM RGCWQREPQQ RHSIKDVHAR
     LQALAQAPPV YLDVLG
//
